Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes.
Stefanich EG, Danilenko DM, Wang H, O'Byrne S, Erickson R, Gelzleichter T, Hiraragi H, Chiu H, Ivelja S, Jeet S, Gadkari S, Hwang O, Fuh F, Looney C, Howell K, Albert V, Balazs M, Refino C, Fong S, Iyer S, Williams M. Stefanich EG, et al. Among authors: danilenko dm. Br J Pharmacol. 2011 Apr;162(8):1855-70. doi: 10.1111/j.1476-5381.2011.01205.x. Br J Pharmacol. 2011. PMID: 21232034 Free PMC article.
Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.
Tang MT, Keir ME, Erickson R, Stefanich EG, Fuh FK, Ramirez-Montagut T, McBride JM, Danilenko DM. Tang MT, et al. Among authors: danilenko dm. Aliment Pharmacol Ther. 2018 Jun;47(11):1440-1452. doi: 10.1111/apt.14631. Epub 2018 Mar 30. Aliment Pharmacol Ther. 2018. PMID: 29601644 Free PMC article. Review.
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade.
Lin WY, Gong Q, Seshasayee D, Lin Z, Ou Q, Ye S, Suto E, Shu J, Lee WP, Lee CW, Fuh G, Leabman M, Iyer S, Howell K, Gelzleichter T, Beyer J, Danilenko D, Yeh S, DeForge LE, Ebens A, Thompson JS, Ambrose C, Balazs M, Starovasnik MA, Martin F. Lin WY, et al. Blood. 2007 Dec 1;110(12):3959-67. doi: 10.1182/blood-2007-04-088088. Epub 2007 Aug 8. Blood. 2007. PMID: 17687108 Free article.
Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases.
Stefanich EG, Rae J, Sukumaran S, Lutman J, Lekkerkerker A, Ouyang W, Wang X, Lee D, Danilenko DM, Diehl L, Loyet KM, Herman A. Stefanich EG, et al. Among authors: danilenko dm. Biochem Pharmacol. 2018 Jun;152:224-235. doi: 10.1016/j.bcp.2018.03.031. Epub 2018 Mar 31. Biochem Pharmacol. 2018. PMID: 29608910
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG. Li D, et al. Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18. Mol Cancer Ther. 2013. PMID: 23598530
99 results